1 Hennepin Healthcare Systems, Minneapolis, Minnesota.
2 Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota.
3 Department of Medicine, Hennepin Healthcare Systems, Minneapolis, Minnesota.
4 Scientific Studies & Projects Group, Symphony Health, Conshohocken, Pennsylvania.
5 Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania.
6 Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
7 Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota.
Sofosbuvir use in patients with decompensated cirrhosis may be associated with reduced liver transplant waitlist mortality and reduced need for transplant.
Data from the Scientific Registry of Transplant Recipients were linked with a national database of pharmacy claims. All adult patients on the liver transplant waiting list on January 1, 2014, or added to the list during 2014, with hepatitis C virus as reason for listing were identified (total n = 2009). A subgroup of 1093 unique patients had consistent pharmacy claim capture and observations. We compared patients who were and were not treated with all sofosbuvir-based regimens.
During the study period, 154 patients received sofosbuvir-based regimens. These patients had lower model for end-stage liver disease scores and significantly longer waiting times. We found a trend toward significance for more sofosbuvir-treated than untreated patients being removed from the waiting list due to improved condition (4.54% vs. 3.19%, P = 0.03). In a propensity-score-adjusted analysis, sofosbuvir-treated patients were less likely to undergo transplant (HR 0.57; 95% CI 0.37-0.89; P = 0.01).
During the study period reflecting early sofosbuvir use, few liver transplant candidates received sofosbuvir. Use was associated with lower incidence of transplant and a trend toward more waitlist removals due to improved condition.